Detalhe da pesquisa
1.
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Lancet
; 393(10174): 889-898, 2019 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686586